Department of Genitourinary/HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, United Kingdom.
Clin Infect Dis. 2011 Mar 1;52(5):671-3. doi: 10.1093/cid/ciq198.
CCR5 antagonists may provide a well-tolerated switch option for patients experiencing tolerability or toxicity of their antiretroviral regimen. We analyzed stored samples from patients undergoing planned treatment interruptions for reasons other than virological failure, in order to analyze tropism evolution during fully suppressive antiretroviral therapy (ART). Two of 37 patients showed evidence of switching. Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA.
CCR5 拮抗剂可能为那些因不耐受或出现药物毒性而需要转换治疗方案的艾滋病患者提供一种耐受性良好的选择。我们分析了因病毒学失败以外的原因而计划中断治疗的患者的储存样本，以分析完全抑制性抗逆转录病毒治疗（ART）期间的病毒学适应性变化。37 名患者中有 2 名出现了适应性转换的证据。在该队列中，在抑制性 ART 后出现适应性转换并不常见。在 HIV RNA 不可检测的患者中，治疗前的 HIV RNA 病毒学适应性检测可能有助于指导转换为 CCR5 拮抗剂。
